<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02565251</url>
  </required_header>
  <id_info>
    <org_study_id>FWA00022929</org_study_id>
    <nct_id>NCT02565251</nct_id>
  </id_info>
  <brief_title>Volemic Resuscitation in Sepsis and Septic Shock</brief_title>
  <official_title>Volemic Resuscitation in Sepsis and Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iuliu Hatieganu University of Medicine and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iuliu Hatieganu University of Medicine and Pharmacy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe sepsis and septic shock are among the leading causes of morbidity and mortality in
      patients admitted in the ICU, being responsible for approximately 200000 deaths/year in the
      USA and 150000 in Europe. Recognizing the early signs of sepsis and the different stages of
      this condition may lower the associated morbidity and mortality.

      The hemodynamic profile of the septic shock is characterized by the presence of the
      distributive shock, on which we can add elements from the hypovolemic and cardiogenic shocks.

      The objecive of this study is to optimize the volemic resuscitation of the severe septic and
      of the septic shock patient using two minimally invasive methods of hemdynamic monitoring
      which both use the same device (Edwards Lifescience). In the same time hemodinamic data will
      be colected by mesuring the inferior vena cava diameter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe sepsis and septic shock are among the leading causes of morbidity and mortality in
      patients admitted in the ICU, being responsible for approximately 200000 deaths/year in the
      USA and 150000 in Europe . Recognizing the early signs of sepsis and the different stages of
      this condition may lower the associated morbidity and mortality.

      The hemodynamic profile of the septic shock is characterized by the presence of the
      distributive shock, on which we can add elements from the hypovolemic and cardiogenic shocks.
      The persistence of hypotension after adequate fluid load is the result of low vascular
      resistance and myocardial dysfunction and calls for certain specific correctional measures.

      The diffrent hemodynamic profiles which can be found in the different stages of the septic
      shock and their dificult clinical identification led to the development of varoius
      hemodynamic monitoring techniques and devices. These techniques can be classified into
      invasive and minimally invasive, calibrated and uncalibrated. The major diffrences among
      these tecniques is the easyness of utilisation and the acuracy of the data obtained.

      Inclusion Criteria: severe sepsis and septic shock (acording to the Sepsis Campaign 2013
      crieria) patients with medical or surgical pathology which are admitted in the ICU unit in
      the first six hours after the onset of the severe sepsis/septic shock. The exclusion criteria
      of the patients are age less then 18 and more then 75, cardiac valvular pathology with
      hemodynamic importance, cardiac failure NYHA III și IV, primary or secondary pulmonary
      hypertension with hemodymanic impact with onset before the onset of the septic
      pathology,severe liver failure (Child-Pugh C), anuric renal failure, pregnant women, patient
      who refuse blood products adminitration, end-stage cancer.

      The objecive of this study is to optimize the volemic resuscitation of the severe septic and
      of the septic shock patient using two minimally invasive methods of hemdynamic monitoring
      which both use the same device (Edwards Lifescience). In the same time hemodinamic data will
      be colected by mesuring the inferior vena cava diameter.

      The primary outcome is the adecuacy of tissue perfusion at six hours (urinary output, blood
      pressure, lactate clearance, skin aspect). The secondary oucomes are duration of
      cardiovascular failure at the end of the 6 hours resuscitation period/ number of days,
      duration of respiratory failure (need of mechanical ventilation, number of days), duration of
      acute renal failure (need of dialysis) at ICU discharge/10/30/60 days, duration of ICU stay
      and in hospital stay, discharge status at 60 days (not discharged ,discharge to another acute
      care hospital, discharged to nursing home, discharged home ,other or unknown and all cause
      mortality at 60 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tissue perfusion at six hours (composite)</measure>
    <time_frame>six hours</time_frame>
    <description>Tissue perfusion at six hours: urinary output, blood pressure, lactate clearance, skin aspect</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of cardiovascular failure</measure>
    <time_frame>at the end of the 6 hours resuscitation period and one, two, six and twelve days</time_frame>
    <description>need of vasopressor support: at the end of the 6 hours resuscitation period and one, two, six and twelve days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of respiratory failure</measure>
    <time_frame>respiratory failure at oane day, two days, six days and twelve days</time_frame>
    <description>respiratory failure at oane day, two days, six days and twelve days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of acute renal failure</measure>
    <time_frame>at 5 days, at 10 days, at 30 days and at 60 days</time_frame>
    <description>Duration of acute renal failure (need of dialysis) at 5 days, at 10 days, at 30 days and at 60 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay and in hospital stay</measure>
    <time_frame>status at 5 days, at 10 days, at 30 days and at 60 days</time_frame>
    <description>Duration of ICU stay and in hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge status at 60 days</measure>
    <time_frame>at 60 days</time_frame>
    <description>Discharge status at 60 days:Not discharged ,Discharge to another acute care hospital,Discharged to nursing home,Discharged home ,Other or unknown</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause mortality at 60 days</measure>
    <time_frame>60 days</time_frame>
    <description>all cause mortality at 60 days</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hemodynamic Instability</condition>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Sepsis grup 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepsis grup 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soc septic grup 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Flotrac/Ev1000 in the first 2 hours and VolumeView/Ev1000 monitoring during the next 4 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Soc septic grup 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodymanic resuscitation giuded by standard ICU monitorisation (BP, CVP) in the first 2 hours andVolumeView/Ev1000 monitoring during the next 4 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Flotrac/Ev1000</intervention_name>
    <description>Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours</description>
    <arm_group_label>Sepsis grup 1</arm_group_label>
    <arm_group_label>Soc septic grup 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard ICU monitorisation</intervention_name>
    <description>Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours</description>
    <arm_group_label>Sepsis grup 2</arm_group_label>
    <arm_group_label>Soc septic grup 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VolumeView/Ev1000</intervention_name>
    <description>Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours</description>
    <arm_group_label>Sepsis grup 1</arm_group_label>
    <arm_group_label>Sepsis grup 2</arm_group_label>
    <arm_group_label>Soc septic grup 1</arm_group_label>
    <arm_group_label>Soc septic grup 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: sepsis and septic shock (acording to the Sepsis Campaign 2016 crieria)
        patients with medical or surgical pathology which are admitted in the ICU unit in the first
        12 hours after the onset of the sepsis/septic shock

        Exclusion Criteria:

        age less then 18 and more then 85 cardiac valvular pathology with hemodynamic importance
        cardiac failure NYHA IV primary or secondary pulmonary hypertension with hemodymanic impact
        with onset before the onset of the septic pathology Severe liver failure (Child-Pugh C)
        Anuric renal failure Pregnant women Patient who refuse blood products adminitration
        End-stage cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Natalia Hagau, Professor</last_name>
    <phone>0742272385</phone>
    <email>hagaunatalia@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cluj County Emenrgency Hospital</name>
      <address>
        <city>Cluj-Napoca</city>
        <state>Cluj</state>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Hagau, Professor</last_name>
      <phone>0742272385</phone>
      <email>hagaunatalia@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <results_reference>
    <citation>Lilly CM. The ProCESS trial--a new era of sepsis management. N Engl J Med. 2014 May 1;370(18):1750-1. doi: 10.1056/NEJMe1402564. Epub 2014 Mar 18.</citation>
    <PMID>24635774</PMID>
  </results_reference>
  <results_reference>
    <citation>ARISE Investigators; ANZICS Clinical Trials Group, Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, Higgins AM, Holdgate A, Howe BD, Webb SA, Williams P. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014 Oct 16;371(16):1496-506. doi: 10.1056/NEJMoa1404380. Epub 2014 Oct 1.</citation>
    <PMID>25272316</PMID>
  </results_reference>
  <results_reference>
    <citation>Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, Jahan R, Harvey SE, Bell D, Bion JF, Coats TJ, Singer M, Young JD, Rowan KM; ProMISe Trial Investigators. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015 Apr 2;372(14):1301-11. doi: 10.1056/NEJMoa1500896. Epub 2015 Mar 17.</citation>
    <PMID>25776532</PMID>
  </results_reference>
  <results_reference>
    <citation>Russell JA. Is there a good MAP for septic shock? N Engl J Med. 2014 Apr 24;370(17):1649-51. doi: 10.1056/NEJMe1402066. Epub 2014 Mar 18.</citation>
    <PMID>24635771</PMID>
  </results_reference>
  <results_reference>
    <citation>Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N, Mira JP, Dequin PF, Gergaud S, Weiss N, Legay F, Le Tulzo Y, Conrad M, Robert R, Gonzalez F, Guitton C, Tamion F, Tonnelier JM, Guezennec P, Van Der Linden T, Vieillard-Baron A, Mariotte E, Pradel G, Lesieur O, Ricard JD, Hervé F, du Cheyron D, Guerin C, Mercat A, Teboul JL, Radermacher P; SEPSISPAM Investigators. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014 Apr 24;370(17):1583-93. doi: 10.1056/NEJMoa1312173. Epub 2014 Mar 18.</citation>
    <PMID>24635770</PMID>
  </results_reference>
  <results_reference>
    <citation>Bakker J, Nijsten MW, Jansen TC. Clinical use of lactate monitoring in critically ill patients. Ann Intensive Care. 2013 May 10;3(1):12. doi: 10.1186/2110-5820-3-12.</citation>
    <PMID>23663301</PMID>
  </results_reference>
  <results_reference>
    <citation>Cecconi M, Arulkumaran N, Kilic J, Ebm C, Rhodes A. Update on hemodynamic monitoring and management in septic patients. Minerva Anestesiol. 2014 Jun;80(6):701-11. Epub 2013 Nov 26. Review.</citation>
    <PMID>24280808</PMID>
  </results_reference>
  <results_reference>
    <citation>Cecconi M, Hofer C, Della Rocca G, Grounds RM, Rhodes A. Assessing agreement in cardiac output monitoring validation studies. J Cardiothorac Vasc Anesth. 2010 Aug;24(4):741; author reply 741-2. doi: 10.1053/j.jvca.2009.11.008. Epub 2010 Jan 22.</citation>
    <PMID>20096600</PMID>
  </results_reference>
  <results_reference>
    <citation>Monnet X, Anguel N, Naudin B, Jabot J, Richard C, Teboul JL. Arterial pressure-based cardiac output in septic patients: different accuracy of pulse contour and uncalibrated pressure waveform devices. Crit Care. 2010;14(3):R109. doi: 10.1186/cc9058. Epub 2010 Jun 10.</citation>
    <PMID>20537159</PMID>
  </results_reference>
  <results_reference>
    <citation>Marqué S, Gros A, Chimot L, Gacouin A, Lavoué S, Camus C, Le Tulzo Y. Cardiac output monitoring in septic shock: evaluation of the third-generation Flotrac-Vigileo. J Clin Monit Comput. 2013 Jun;27(3):273-9. doi: 10.1007/s10877-013-9431-z. Epub 2013 Jan 30.</citation>
    <PMID>23361128</PMID>
  </results_reference>
  <results_reference>
    <citation>Antonelli M, Levy M, Andrews PJ, Chastre J, Hudson LD, Manthous C, Meduri GU, Moreno RP, Putensen C, Stewart T, Torres A. Hemodynamic monitoring in shock and implications for management. International Consensus Conference, Paris, France, 27-28 April 2006. Intensive Care Med. 2007 Apr;33(4):575-90.</citation>
    <PMID>17285286</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2015</study_first_posted>
  <last_update_submitted>December 13, 2016</last_update_submitted>
  <last_update_submitted_qc>December 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iuliu Hatieganu University of Medicine and Pharmacy</investigator_affiliation>
    <investigator_full_name>Platon Oana</investigator_full_name>
    <investigator_title>Antal Oana MD</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>hemodynamic monitoring</keyword>
  <keyword>septic shock</keyword>
  <keyword>volemic resuscitation</keyword>
  <keyword>fluid resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

